Health Partners

### HEALTH PARTNERS PLANS 2024 PRIOR AUTHORIZATION REQUEST FORM

A part of Jefferson Health Plans

# Evrysdi (non-pdl)

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:		Prescriber Na	me:	
HPP HPP Member Number:		Fax:	Phone:	
Date of Birth:		Office Contact	t:	
Patient Primary Phone:		NPI:	PA PROMISe ID:	
Address:		Address:		
City, State ZIP:		City, State ZIF	).	
Line of Business:   Medicaid	CHIP	Specialty Pha	rmacy (if applicable):	
Drug Name:		Strength:		
Quantity:		Refills:		
Directions:				
Diagnosis Code:	Diagnosis:			
HPP's maximum approval time is 12 months but may be less depending on the drug.				

Please attach any pertinent medical history including labs and information for this member that may support approval. Please answer the following questions and sign.			
Q1. Is the medication prescribed by or in consultation with a neurologist or physician who specializes in treatment of spinal muscular atrophy?			
□ Yes □ No			
Q2. Select the prescribed dose that is being given from the recommended dosing per Evrysdi™ (risdiplam) prescribing information:			
☐ If under 2 months of age, dose does not exceed 0.15 mg/kg per day			
☐ If 2 months of age to less than 2 years of age, dose does not exceed 0.2 mg/kg per day			
$\Box$ If 2 years of age and older, weighing less than 20 kg, dose does not exceed 0.25 mg/kg			
per day			
☐ If 2 years of age and older, weighing 20 kg or more, dose does not exceed 5 mg per day ☐ Other			
Q3. Does the patient receive comprehensive treatment based on standards of care for spinal muscular dystrophy?			
□ Yes □ No			
Q4. Request Type:			

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



#### HEALTH PARTNERS PLANS 2024 PRIOR AUTHORIZATION REQUEST FORM

A part of Jefferson Health Plans

# Evrysdi (non-pdl)

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician.
Please answer the following questions and fax this form to the number listed above.

#### PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:			
🗌 Initial	□ Renewal - Skip to 8			
Q5. Does the member have a diagnosis of spinal muscular atrophy type I, II, or III?				
□ Yes	□ No			
Q6. Is the patient's diagnosis of spinal muscular atrophy confirmed by laboratory documentation of homozygous deletion or mutation of SMN 1 gene?				
□ Yes	□ No			
Q7. Select all the criteria that apply:				
☐ Member is not concurrently being treated with gene therapy, including Spinraza® and/or Zolgensma®, or currently enrolled in a clinical trial to receive gene therapy for SMA	☐ Member previously received gene therapy and was unable to maintain beneficial response in SMA-associated symptoms as documented by chart notes			
Q8. For Renewals, does the patient continue to meet the diagnostic criteria?				
□ Yes	□ No			
Q9. For Renewals, is the patient receiving clinical benefit based on the prescriber's assessment?				
□ Yes	□ No			
Q10. For Renewals, does the patient have the absence of unacceptable toxicity which precludes safe administration of the drug?				
□ Yes	□ No			
Q11. Additional Information:				

Prescriber Signature

Date

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



#### HEALTH PARTNERS PLANS 2024 PRIOR AUTHORIZATION REQUEST FORM



## Evrysdi (non-pdl)

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:

Updated for 2024

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document